Colorectal cancer statistics, 2017.
Rebecca L. Siegel,Kimberly D. Miller,Stacey A. Fedewa,Dennis J. Ahnen,Reinier G.S. Meester,Afsaneh Barzi,Ahmedin Jemal +6 more
TLDR
Overall CRC incidence in individuals ages ≥50 years declined from 2009 to 2013 in every state except Arkansas, with the decrease exceeding 5% annually in 7 states; however, rectal tumor incidence in those ages 50 to 64 years was stable in most states.Abstract:
Colorectal cancer (CRC) is one of the most common malignancies in the United States. Every 3 years, the American Cancer Society provides an update of CRC incidence, survival, and mortality rates and trends. Incidence data through 2013 were provided by the Surveillance, Epidemiology, and End Results program, the National Program of Cancer Registries, and the North American Association of Central Cancer Registries. Mortality data through 2014 were provided by the National Center for Health Statistics. CRC incidence rates are highest in Alaska Natives and blacks and lowest in Asian/Pacific Islanders, and they are 30% to 40% higher in men than in women. Recent temporal patterns are generally similar by race and sex, but differ by age. Between 2000 and 2013, incidence rates in adults aged ≥50 years declined by 32%, with the drop largest for distal tumors in people aged ≥65 years (incidence rate ratio [IRR], 0.50; 95% confidence interval [95% CI], 0.48-0.52) and smallest for rectal tumors in ages 50 to 64 years (male IRR, 0.91; 95% CI, 0.85-0.96; female IRR, 1.00; 95% CI, 0.93-1.08). Overall CRC incidence in individuals ages ≥50 years declined from 2009 to 2013 in every state except Arkansas, with the decrease exceeding 5% annually in 7 states; however, rectal tumor incidence in those ages 50 to 64 years was stable in most states. Among adults aged <50 years, CRC incidence rates increased by 22% from 2000 to 2013, driven solely by tumors in the distal colon (IRR, 1.24; 95% CI, 1.13-1.35) and rectum (IRR, 1.22; 95% CI, 1.13-1.31). Similar to incidence patterns, CRC death rates decreased by 34% among individuals aged ≥50 years during 2000 through 2014, but increased by 13% in those aged <50 years. Progress against CRC can be accelerated by increasing initiation of screening at age 50 years (average risk) or earlier (eg, family history of CRC/advanced adenomas) and eliminating disparities in high-quality treatment. In addition, research is needed to elucidate causes for increasing CRC in young adults. CA Cancer J Clin 2017. © 2017 American Cancer Society. CA Cancer J Clin 2017;67:177-193. © 2017 American Cancer Society.read more
Citations
More filters
Journal ArticleDOI
Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement
Kirsten Bibbins-Domingo,David C. Grossman,Susan J. Curry,Karina W. Davidson,John W. Epling,Francisco A.R. Garcia,Matthew W. Gillman,Diane M. Harper,Alex R. Kemper,Alex H. Krist,Ann E. Kurth,C. Seth Landefeld,Carol M. Mangione,Douglas K Owens,Douglas K Owens,William R. Phillips,Maureen G. Phipps,Michael Pignone,Albert L. Siu,Albert L. Siu +19 more
TL;DR: It is concluded with high certainty that screening for colorectal cancer in average-risk, asymptomatic adults aged 50 to 75 years is of substantial net benefit.
Journal ArticleDOI
Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society
Andrew M.D. Wolf,Elizabeth T. H. Fontham,Timothy R. Church,Christopher R. Flowers,Carmen Guerra,Samuel J. LaMonte,Ruth Etzioni,Matthew T. McKenna,Kevin C. Oeffinger,Ya Chen Tina Shih,Louise C. Walter,Kimberly S. Andrews,Otis W. Brawley,Durado Brooks,Stacey A. Fedewa,Deana Manassaram-Baptiste,Rebecca L. Siegel,Richard C. Wender,Robert A. Smith +18 more
TL;DR: This guideline update used an existing systematic evidence review of the CRC screening literature and microsimulation modeling analyses, including a new evaluation of the age to begin screening by race and sex and additional modeling that incorporates changes in US CRC incidence.
Journal ArticleDOI
Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics
Kathleen A. Cronin,Andrew J. Lake,Susan Scott,Recinda L. Sherman,Anne-Michelle Noone,Nadia Howlader,S. Jane Henley,Robert N. Anderson,Albert U. Firth,Jiemin Ma,Betsy A. Kohler,Ahmedin Jemal +11 more
TL;DR: The American Cancer Society, the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate to provide annual updates on cancer occurrence and trends in the United States.
Journal ArticleDOI
Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis.
TL;DR: The mechanistic links between bile acids and gastrointestinal carcinogenesis in CRC and HCC are discussed, which involve two major bile acid-sensing receptors, farnesoid X receptor (FXR) and G protein-coupled bile Acid receptor 1 (TGR5).
Journal ArticleDOI
Cancer nanomedicine: a review of recent success in drug delivery
TL;DR: The clinical trials of Onivyde leading to its approval in 2015 by the Food and Drug Adminstration are highlighted as a case study in the recent clinical success of nanomedicine against cancer.
References
More filters
Journal ArticleDOI
Cancer statistics, 2017
TL;DR: The American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival.
Journal ArticleDOI
Cancer treatment and survivorship statistics, 2016.
Kimberly D. Miller,Rebecca L. Siegel,Chun Chieh Lin,Angela B. Mariotto,Joan L. Kramer,Julia H. Rowland,Kevin Stein,Rick Alteri,Ahmedin Jemal +8 more
TL;DR: The number of cancer survivors continues to increase because of both advances in early detection and treatment and the aging and growth of the population and for the public health community to better serve these survivors, the American Cancer Society and the National Cancer Institute collaborate to estimate the number of current and future cancer survivors.
Journal ArticleDOI
Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
Rolf Sauer,Heinz Becker,Werner Hohenberger,Claus Rödel,Christian Wittekind,Rainer Fietkau,Peter Martus,Jörg Tschmelitsch,Eva Hager,Clemens F. Hess,Torsten Liersch,Heinz Schmidberger,Rudolf Raab +12 more
TL;DR: Preoperative chemoradiotherapy, as compared with postoperative cheMoradi therapy, improved local control and was associated with reduced toxicity but did not improve overall survival.
Journal ArticleDOI
Global patterns and trends in colorectal cancer incidence and mortality
Melina Arnold,Mónica S. Sierra,Mathieu Laversanne,Isabelle Soerjomataram,Ahmedin Jemal,Freddie Bray +5 more
TL;DR: Pattern and trends in CRC incidence and mortality correlate with present human development levels and their incremental changes might reflect the adoption of more western lifestyles, pointing towards widening disparities and an increasing burden in countries in transition.
Journal ArticleDOI
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
Thierry André,Corrado Boni,Lamia Mounedji-Boudiaf,Matilde Navarro,Josep Tabernero,Tamas Hickish,C. Topham,Marta Zaninelli,Phillip Clingan,John Bridgewater,Isabelle Tabah-Fisch,Aimery de Gramont +11 more
TL;DR: Adding oxaliplatin to a regimen of fluorouracil and leucovorin improves the adjuvant treatment of colon cancer.